Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results Acq. announced Director departure Appointed director
|
PhaseBio Pharmaceuticals Inc (PHAS)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 0% stake in PhaseBio Pharmaceuticals, Inc. |
02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 4.1% stake in PhaseBio Pharmaceuticals, Inc. |
02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
07/19/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/14/2022 |
SC 13G/A
| Rock Springs Capital Management LP reports a 5.4% stake in PhaseBio Pharmaceuticals, Inc. |
02/14/2022 |
SC 13G/A
| Rosalind Advisors, Inc. reports a 1.5% stake in PhaseBio Pharmaceuticals, Inc. |
02/14/2022 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 5.9% stake in PhaseBio Pharmaceuticals, Inc. |
02/11/2022 |
SC 13G/A
| Avidity Partners Management LP reports a 9.2% stake in PhaseBio Pharmaceuticals, Inc. |
02/01/2022 |
SC 13G/A
| JOHNSON & JOHNSON reports a 3.3% stake in PhaseBio Pharmaceuticals, Inc. |
11/10/2021 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 4% stake in PhaseBio Pharmaceuticals Inc |
08/10/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/16/2021 |
SC 13G/A
| Rock Springs Capital Management LP reports a 4.5% stake in PhaseBio Pharmaceuticals, Inc. |
01/11/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/14/2020 |
SC 13G/A
| Rock Springs Capital Management LP reports a 3.9% stake in PhaseBio Pharmaceuticals, Inc. |
01/27/2020 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 13.5% stake in PhaseBio Pharmaceuticals Inc |
01/17/2020 |
SC 13G/A
| JOHNSON & JOHNSON reports a 5.6% stake in PhaseBio Pharmaceuticals, Inc. |
02/12/2019 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 13.8% stake in PhaseBio Pharmaceuticals Inc |
|
|